Sequential Skin Ltd, a UK/Singapore biotech start-up, has raised US $1.65M in its oversubscribed seed round led by Metaplanet, and supported by Scrum Ventures, SOSV, Genedant, and angel investor, Ben Holmes (ex. General Partner at Index Ventures). This latest investment brings the total venture funding raised by Sequential Skin to US $2.15M in 2021.
The investment will be used to extend their B2B offering to skincare, haircare and healthcare companies, adding to the twelve major clients currently using Sequential Skin. Sequential Skin will also be rolling out their consumer product, with a focus on expanding into the US via New York City, the statement said.
“The world of skincare is flooded with a confusing array of products that only help some of the people, some of the time,” said Rauno Miljand, Metaplanet Managing Partner. “We’re proud to lead the investment in Sequential Skin. It is the first company, using genomics and microbiome skin assays, that identifies to consumers the exact products suited for each individual.”
“We now have significant traction in assembling an extensive dataset on skin types from Asia, Europe and the US—a great chance for us to discover novel biomarkers for skin conditions in different populations,” said Dr Oliver Worsley, CEO and cofounder.
The funding will significantly boost their IP portfolio, using their novel patch-based, skin analysis, to develop further tools to understand how your genetics, epigenetics and skin microbiome, affect health and disease, a statement added.
Dr Albert Dashi, CSO and cofounder, added: “Our scope is to provide science to people and empower them with the right tools and knowledge so they make the right decision for the future of their skin health and well-being.”
